Opening question: When a research-peptide listing flashes a SigniSite “key residue” heatmap or genotype–phenotype logo, how do you tell residue-association literacy apart from proof the vial is cleared for people?
Short answer: open the live SigniSite 2.1 server at DTU Health Tech and the paper it asks you to cite, Jessen et al., Nucleic Acids Research (2013). SigniSite identifies amino-acid residues in a protein multiple sequence alignment that are significantly associated with a real-valued phenotype for that sequence set. That is MSA genotype–phenotype literacy. It is not a medicines review of a catalog SKU.
A practical SigniSite checklist when listings lean on residue-heatmap screenshots:
- Alignment + phenotype required: Input is a FASTA multiple sequence alignment with phenotype values. A single research-peptide sequence without an MSA and phenotype table is not a SigniSite analysis.
- Association ≠ causation ≠ clearance: Significant residue–phenotype correlations describe patterns in the submitted set. They do not prove a commercial peptide treats a disease or is authorized for people.
- Reference-sequence numbering: Optional reference sequences renumber heatmap/logo positions. Cropped plots without that reference make “residue 42” claims hard to audit.
- Different from property calculators: ProtParam/ProtScale/NetSurfP summarize physicochemical or structural features of a sequence. SigniSite asks which residues track a phenotype across an alignment—related literacy, different question.
- What to open next: If a listing implies a research peptide is “SigniSite-cleared,” open the live SigniSite 2.1 page and Jessen et al. and ask whether the claim teaches residue–phenotype correlation—or borrows heatmap jargon for human-use meaning.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use SigniSite to understand residue-level phenotype associations in MSAs, then notice whether the listing is teaching that method—or dressing a research chemical with “key residue” heatmaps. That habit changes what you verify before trusting a SigniSite badge—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the SigniSite 2.1 service page, the DTU bioinformatic services index, and Jessen et al. NAR 2013 (DOI 10.1093/nar/gkt497) (fetched 2026-10-02 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. SigniSite 2.1 — DTU Health Tech
2. Jessen et al., Nucleic Acids Research 2013 (DOI 10.1093/nar/gkt497)
3. DTU Health Tech — Bioinformatic Tools and Services
4. Apollo Peptides (company facts only)
Related reading
ProtParam sequence property screenshots beside research listings
NetSurfP surface accessibility screenshots beside research listings
ProtScale amino-acid scale profiles beside research listings